111 related articles for article (PubMed ID: 24129914)
1. Recombinant human kallistatin inhibits angiogenesis by blocking VEGF signaling pathway.
Huang KF; Yang HY; Xing YM; Lin JS; Diao Y
J Cell Biochem; 2014 Mar; 115(3):575-84. PubMed ID: 24129914
[TBL] [Abstract][Full Text] [Related]
2. Kallistatin, a novel anti-angiogenesis agent, inhibits angiogenesis via inhibition of the NF-κB signaling pathway.
Huang KF; Huang XP; Xiao GQ; Yang HY; Lin JS; Diao Y
Biomed Pharmacother; 2014 May; 68(4):455-61. PubMed ID: 24721321
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
4. The recombinant kringle domain of urokinase plasminogen activator inhibits VEGF165-induced angiogenesis of HUVECs by suppressing VEGFR2 dimerization and subsequent signal transduction.
Kim BM; Lee DH; Choi HJ; Lee KH; Kang SJ; Joe YA; Hong YK; Hong SH
IUBMB Life; 2012 Mar; 64(3):259-65. PubMed ID: 22252975
[TBL] [Abstract][Full Text] [Related]
5. Kallistatin exerts anti-lymphangiogenic effects by inhibiting lymphatic endothelial cell proliferation, migration and tube formation.
Ma C; Yin H; Zhong J; Zhang Y; Luo C; Che D; Fang Z; Li L; Qin S; Liang J; Qi W; Yang Z; Zhou T; Ma J; Yang X; Gao G
Int J Oncol; 2017 Jun; 50(6):2000-2010. PubMed ID: 28440474
[TBL] [Abstract][Full Text] [Related]
6. Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway.
Li M; Wu S; Liu Z; Zhang W; Xu J; Wang Y; Liu J; Zhang D; Tian H; Li Y; Ye W
Biochem Pharmacol; 2012 May; 83(9):1251-60. PubMed ID: 22305746
[TBL] [Abstract][Full Text] [Related]
7. Glycation of vitronectin inhibits VEGF-induced angiogenesis by uncoupling VEGF receptor-2-αvβ3 integrin cross-talk.
Wang L; Zhang X; Pang N; Xiao L; Li Y; Chen N; Ren M; Deng X; Wu J
Cell Death Dis; 2015 Jun; 6(6):e1796. PubMed ID: 26111058
[TBL] [Abstract][Full Text] [Related]
8. [Expression of recombinant human kallistatin in Pichia pastoris by high density cell culture, and its purification and characterization].
Zhang Q; Xing YM; Liu J; Diao Y
Yao Xue Xue Bao; 2013 Jul; 48(7):1107-12. PubMed ID: 24133976
[TBL] [Abstract][Full Text] [Related]
9. Magnolol suppresses vascular endothelial growth factor-induced angiogenesis by inhibiting Ras-dependent mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways.
Kim KM; Kim NS; Kim J; Park JS; Yi JM; Lee J; Bang OS
Nutr Cancer; 2013; 65(8):1245-53. PubMed ID: 24066970
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic activity of carebastine: a plausible mechanism affecting airway remodelling.
De Luisi A; Mangialardi G; Ria R; Acuto G; Ribatti D; Vacca A
Eur Respir J; 2009 Oct; 34(4):958-66. PubMed ID: 19357149
[TBL] [Abstract][Full Text] [Related]
11. TRAIL negatively regulates VEGF-induced angiogenesis via caspase-8-mediated enzymatic and non-enzymatic functions.
Na HJ; Hwang JY; Lee KS; Choi YK; Choe J; Kim JY; Moon HE; Kim KW; Koh GY; Lee H; Jeoung D; Won MH; Ha KS; Kwon YG; Kim YM
Angiogenesis; 2014 Jan; 17(1):179-94. PubMed ID: 24097299
[TBL] [Abstract][Full Text] [Related]
12. Endothelium-derived nitric oxide (NO) activates the NO-epidermal growth factor receptor-mediated signaling pathway in bradykinin-stimulated angiogenesis.
Moraes MS; Costa PE; Batista WL; Paschoalin T; Curcio MF; Borges RE; Taha MO; Fonseca FV; Stern A; Monteiro HP
Arch Biochem Biophys; 2014 Sep; 558():14-27. PubMed ID: 24960080
[TBL] [Abstract][Full Text] [Related]
13. VEGF111b, a new member of VEGFxxxb isoforms and induced by mitomycin C, inhibits angiogenesis.
Gu F; Li X; Kong J; Pan B; Sun M; Zheng L; Yao Y
Biochem Biophys Res Commun; 2013 Nov; 441(1):18-24. PubMed ID: 24125722
[TBL] [Abstract][Full Text] [Related]
14. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
15. Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway.
Zhang J; Ye J; Ma D; Liu N; Wu H; Yu S; Sun X; Tse W; Ji C
Carcinogenesis; 2013 Mar; 34(3):667-77. PubMed ID: 23239744
[TBL] [Abstract][Full Text] [Related]
16. FAS1 domain protein inhibits VEGF165-induced angiogenesis by targeting the interaction between VEGFR-2 and αvβ3 integrin.
Nam JO; Son HN; Jun E; Cha K; Lee BH; Park RW; Kim IS
Mol Cancer Res; 2012 Aug; 10(8):1010-20. PubMed ID: 22710795
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenic effect of furanodiene on HUVECs in vitro and on zebrafish in vivo.
Zhong ZF; Hoi PM; Wu GS; Xu ZT; Tan W; Chen XP; Cui L; Wu T; Wang YT
J Ethnopharmacol; 2012 Jun; 141(2):721-7. PubMed ID: 21911050
[TBL] [Abstract][Full Text] [Related]
18. BRN-103, a novel nicotinamide derivative, inhibits VEGF-induced angiogenesis and proliferation in human umbilical vein endothelial cells.
Choi HE; Yoo MS; Choi JH; Lee JY; Kim JH; Kim JH; Lee JK; Kim GI; Park Y; Chi YH; Paik SH; Lee JH; Lee KT
Bioorg Med Chem Lett; 2011 Nov; 21(21):6236-41. PubMed ID: 21963305
[TBL] [Abstract][Full Text] [Related]
19. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
Li X; Wang X; Ye H; Peng A; Chen L
Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of vascular endothelial growth factor-induced angiogenesis by scopoletin through interrupting the autophosphorylation of VEGF receptor 2 and its downstream signaling pathways.
Pan R; Dai Y; Gao XH; Lu D; Xia YF
Vascul Pharmacol; 2011; 54(1-2):18-28. PubMed ID: 21078410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
